CG Oncology CGON Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -4,239%+483pp | -4,722.1%+3,563pp | -8,285.3%+20,261pp | -28,546.1%-8,244pp | -20,302.3%-10,235pp | |
| Net margin | -3,682.6%+302pp | -3,985%+2,983pp | -6,968%+16,277pp | -23,245.2%-7,300pp | -15,945.2%-8,216pp | |
| EBITDA margin | -4,194.4%+492pp | -4,686.4%+3,572pp | -8,257.9%+20,252pp | -28,509.6%-8,215pp | -20,294.4%-10,230pp | |
| Free cash flow margin | -3,163.8%+115pp | -3,279.2%+2,108pp | -5,387.7%+11,682pp | -17,069.9%-4,651pp | -12,419.3%-5,488pp | |
| Returns | ||||||
| Return on equity | -20.8%+0.9pp | -21.7%+3.1pp | -24.7%-3.8pp | -21%-4.4pp | -16.6%— | |
| Return on assets | -20%+0.8pp | -20.8%+2.8pp | -23.6%-3.4pp | -20.2%-4.1pp | -16.1%+2.3pp | |
| Return on invested capital | -24.9%+6.8pp | -31.7%-0.2pp | -31.5%-4.9pp | -26.6%-3.3pp | -23.2%— | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 31.3×+6.7× | 24.6×+1.8× | 22.8×+0.6× | 22.2×-8.8× | 31×-4.3× | |
| Quick ratio | 31.3×+6.7× | 24.6×+1.8× | 22.7×+0.6× | 22.2×-8.8× | 31×-4.3× | |
| Cash ratio | 1×-0.1× | 1.1×-0.4× | 1.5×+1.0× | 0.5×-1.4× | 1.8×-10.2× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $12.92+32.7% | $9.74+8.6% | $8.96+1.9% | $8.79-4.9% | $9.25-21.2% | |
| Valuation | ||||||
| Market capitalization | $5.71B+70.6% | $3.35B+9.1% | $3.07B+56.2% | $1.97B+5.4% | $1.87B-14.5% | |
| Enterprise value | $5.69B+71.1% | $3.32B+9.6% | $3.03B+55.3% | $1.95B+6.9% | $1.83B-5.2% | |
| Price / sales | 1,126.9×+298× | 829×-584× | 1,412.7×-2,156× | 3,569.2×+750× | 2,819.6×+903× | |
| Price / book | 5.2×+0.8× | 4.5×0.0× | 4.5×+1.5× | 2.9×+0.3× | 2.6×-0.3× | |
| EV / sales | 1,121.8×+299× | 822.7×-573× | 1,395.3×-2,149× | 3,544.4×+786× | 2,758.5×+1,067× | |
| Free cash flow yield | -2.8%+1.1pp | -4%-0.1pp | -3.8%+1.0pp | -4.8%-0.4pp | -4.4%-0.8pp | |
| Earnings yield | -3.3%+1.5pp | -4.8%+0.1pp | -4.9%+1.6pp | -6.5%-0.9pp | -5.7%-1.6pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do CG Oncology's ratios come from?
- Every ratio is computed from CG Oncology's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.